Organoidsciences Ltd.

As of June 30, 2026, Organoidsciences Ltd. carries a market capitalization of 63.55B, placing it among publicly traded companies globally. Its enterprise value stands at 46.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Organoidsciences Ltd. has 6.59M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 27.71, and the price-to-book ratio stands at 2.26.

These figures are as of June 30, 2026. The EV/Sales ratio of 20.16 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 46.14B versus a market cap of 63.55B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Organoidsciences Ltd. maintains a current ratio of 5.07, meaning it holds 5.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 57.68, indicating elevated leverage, while an interest coverage ratio of -26.73 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Organoidsciences Ltd. posted a negative return on equity (ROE) of -61.59, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -36.80, reflecting losses generated across the asset base. The company generates approximately 25.94M in revenue per employee across its workforce of 88.25, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Organoidsciences Ltd.'s stock has declined approximately 82.84% over the past 52 weeks. The 50-day moving average sits at 6,892.60, while the 200-day moving average is 17,762.25.

Over the twelve months ended June 30, 2026, Organoidsciences Ltd. generated 2.29B in revenue and converted that into -18.65B in net income, yielding earnings per share of -2,866.22. EBITDA reached -15.96B, while operating income came in at -16.35B.

As of June 30, 2026, Organoidsciences Ltd. holds 33.81B in cash and equivalents against 16.27B in total debt, resulting in a net debt position of 11.87B. Total book value stands at 28.09B, with working capital of 28.83B providing operational flexibility.

Organoidsciences Ltd. produced -13.58B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.70B in capital expenditures, free cash flow totaled -18.29B - equivalent to -2,781.84 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -714.26 and net profit margin of -814.80 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -28.83: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -47.65, meaning Organoidsciences Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Organoidsciences Ltd. has an Altman Z-Score of -1.90, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.